The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events.

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Due to an ongoing investigation of serious adverse events, it is recommended that the use of Ixchiq ® (chikungunya ... for Disease Control and Prevention (CDC). According to the Agencies, as ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

the ACIP voted to recommend a precaution related to the use of Ixchiq in patients aged 65 years and older due to an ongoing investigation by the CDC of 6 cases of serious adverse events ...

ACIP maintained ... to the use of IXCHIQ ® in persons aged ≥65 years. This precaution is a response to an ongoing investigation by the CDC of six cases of serious adverse events (SAEs ...

Recommendations for the use of chikungunya vaccine were recently discussed at a meeting of the Advisory Committee on Immunization Practices.

The ACIP also voted to recommend a precaution related to the use of IXCHIQ ® in persons aged ≥65 years. This precaution is a response to an ongoing investigation by the CDC of six cases of serious ...